IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
A phase 3 trial testing IBI354 in HER2-positive breast cancer, now recruiting.
Overview
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer is a phase 3 interventional study registered as NCT07377643, led by Innovent Biopharmaceutical Technology (Hangzhou), and recruiting when checked on 2026-09-11. Official title: A Randomised, Multicenter, Open-label Phase 3 Study to Compare IBI354 With or Without Pertuzumab vs. Taxane in Combination With Trastuzumab and Pertuzumab as First-line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Breast Cancer. Planned enrolment is 540 participants (estimated). The study started in 2026-02-10 and primary completion is expected in 2028-04-28. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialStudy of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Shares IBI354, Innovent Biologics and the tag ctgov-ingest.
- TrialA Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Shares Innovent Biologics and the tag ctgov-ingest.
- TrialA Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment
Shares Innovent Biologics and the tag ctgov-ingest.
- TrialA Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialJSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialEfficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.